Dr. Riordan is responsible for bringing together Worldwide’s scientific assets across CNS, General Medicine, Cardiometabolics, and Oncology Franchises and connecting the critical functions that serve to differentiate Worldwide by implementing strategies and tactics consistent with our vision of being the leader in the application of rigorous methodology and medically/scientifically advanced drug development processes producing reliable data to support highly informed health care decisions.
He has been involved in the assessment, treatment and investigation of various CNS disorders in both industry and academia for more than 20 years; was one of the original Worldwide team members beginning in 1998, and a cofounder of the current Worldwide.
Dr. Riordan has been the primary author of numerous protocols in neurologic, psychiatric and analgesic indications across all phases of development. He has been involved in several clinical development programs and has participated in numerous advisory boards and regulatory interactions. He has advanced training in quantitative methods, biostatistics, experimental design, neurophysiology, neuroimaging and clinical neuropsychology and has published over 120 peer-reviewed abstracts, articles, book chapters and books.
Prior to joining the late phase team he was the clinical lead for Worldwide’s early phase development unit, where he was responsible for helping to establish their specialized patient study unit. He also spent several years in the departments of neurology and psychiatry at Jefferson, the University of Pennsylvania and Dartmouth medical schools.